Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IRONWOOD PHARMACEUTICALS, INC.

(IRWD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IRONWOOD PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

12/01/2021 | 07:39am EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 29, 2021, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the "Company") appointed Sravan K. Emany, 44, as the Company's Senior Vice President, Chief Financial Officer, effective December 6, 2021 (the "Effective Date"). On the Effective Date, Mr. Emany will assume the responsibilities of the Company's principal financial officer from Jason Rickard, who will remain the Company's Senior Vice President, Chief Operating Officer.

Prior to joining the Company, Mr. Emany served as corporate vice president, commercial excellence and chief strategy officer of Integra LifeSciences Holdings Corporation, a publicly held global healthcare company, since March 2020, and as vice president of strategy, treasury and investor relations from February 2018 to March 2020. Prior to that, Mr. Emany served in various mergers and acquisitions investment banking roles in Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group, Deutsche Bank Securities, Lazard, and Morgan Stanley. Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies (SAIS).

Mr. Emany will receive a base salary of $500,000 a year and will have an individual bonus target of 50% of his base salary, subject to achievement of individual and corporate goals. Mr. Emany will also receive a one-time bonus of $200,000 in connection with his joining the Company, which is subject to certain clawback provisions if Mr. Emany terminates his employment with the Company for any reason or if he is terminated by the Company for cause, in each case, within two years of the Effective Date. Mr. Emany will receive grants under the Company's 2019 Equity Incentive Plan of 85,000 restricted stock units ("RSUs") that will vest as to 25% of the RSUs on each of the first four approximate anniversaries of the date of grant and 85,000 performance-based restricted stock units ("PSUs"), the vesting terms of which will be consistent with those applicable to the 2021 PSU awards described in the Company's proxy statement (the "Proxy Statement") filed with the Securities and Exchange Commission (the "SEC") on April 22, 2021. Each RSU and PSU represents a contingent right to receive shares of the Company's Class A common stock upon vesting of such awards.

In addition, the Company will enter into an indemnification agreement and an executive severance agreement with Mr. Emany. The terms of the indemnification agreement will be consistent with the form of indemnification agreement described in the Proxy Statement, such description being incorporated herein by reference and qualified in its entirety by the full text of the form of indemnification agreement that was filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1 (as amended) filed with the SEC on December 23, 2009.

The terms of the executive severance agreement will be consistent with the Company's revised form of severance agreement applicable to all executive officers of the Company who have joined the Company following July 20, 2021. The executive severance agreement will provide that, in the event of a qualifying termination, Mr. Emany would be entitled to receive the following benefits under the executive severance agreement: (i) a lump-sum payment equal to twelve (12) months of his base salary at the rate in effect as of the date of termination of employment (or, if Mr. Emany's termination constitutes a Change of Control Termination, as defined in the executive severance agreement, a lump-sum payment equal to eighteen (18) months of his base salary); (ii) a lump-sum payment equal to his actual bonus for the prior year if not yet paid as of the termination date; (iii) a lump-sum payment equal to his target cash bonus for the year of termination, pro-rated based on the percentage of the year worked prior to the triggering event; (iv) a lump-sum payment equal to his full target cash bonus for the year of termination (or, if Mr. Emany's termination constitutes a Change of Control Termination, a lump-sum payment equal to his full target cash bonus for the year of termination, multiplied by 1.5); (v) up to twelve (12) months of subsidized COBRA coverage benefits (or, if Mr. Emany's termination constitutes a Change of Control Termination, eighteen (18) months of subsidized COBRA coverage benefits); and (vi) outplacement assistance benefits. In addition, if Mr. Emany's termination constitutes a Change of Control Termination, the executive severance agreement will provide for the acceleration of all outstanding equity awards subject solely to time-based vesting as of the later of (1) the termination date, or (2) the Change of Control (as defined in the agreement).

The foregoing description of Mr. Emany's executive severance agreement does not purport to be complete and is qualified in its entirety by the full text of the form of executive severance agreement, which is filed as exhibit 10.1 to this Current Report on Form 8-K.

There is no arrangement or understanding between Mr. Emany and any other person pursuant to which Mr. Emany was appointed as the Company's Senior Vice President, Chief Financial Officer. There is no family relationship between Mr. Emany and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company. Mr. Emany is not, and has not been since January 1, 2020, a participant in any transaction involving the Company, and is not a participant in any proposed transaction with the Company, required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

Item 9.01 Financial Statements and Exhibits



(d)  Exhibits.



Exhibit No.        Description
   10.1              Form of Executive Severance Agreement
    104            The cover page from this Current Report on Form 8-K, formatted in
                   Inline XRBL

© Edgar Online, source Glimpses

All news about IRONWOOD PHARMACEUTICALS, INC.
01/10Ironwood Pharmaceuticals Sees 2021 Revenue at High-End of Previous Guidance; Guides for..
MT
01/10IRONWOOD PHARMACEUTICALS : Provides Update on FY 2021 Financial Guidance and Announces FY ..
PU
01/10Tranche Update on Ironwood Pharmaceuticals, Inc.'s Equity Buyback Plan announced on May..
CI
01/10Ironwood Pharmaceuticals, Inc. Updates Financial Guidance for the Full Year 2021
CI
01/10Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022
CI
01/10Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY..
BU
01/05Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conferenc..
BU
2021INSIDER SELL : Ironwood Pharmaceuticals
MT
2021Ironwood Pharmaceuticals Hires Sravan Emany as Chief Financial Officer
MT
2021IRONWOOD PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statem..
AQ
More news
Analyst Recommendations on IRONWOOD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 407 M - -
Net income 2021 540 M - -
Net cash 2021 119 M - -
P/E ratio 2021 3,36x
Yield 2021 -
Capitalization 1 792 M 1 792 M -
EV / Sales 2021 4,11x
EV / Sales 2022 3,27x
Nbr of Employees 232
Free-Float 98,5%
Chart IRONWOOD PHARMACEUTICALS, INC.
Duration : Period :
Ironwood Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRONWOOD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 10,95 $
Average target price 13,00 $
Spread / Average Target 18,7%
EPS Revisions
Managers and Directors
Thomas A. McCourt President, Chief Executive Officer & Director
Sravan Kumar Emany Chief Financial Officer & Senior Vice President
Julie Harris McHugh Executive Chairman
Michael Shetzline Chief Medical Officer & Senior Vice President
Cristina Almansa Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
IRONWOOD PHARMACEUTICALS, INC.-8.75%1 741
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892